Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hackensack Meridian Health
With
Canary Speech Inc.
The study aims to assess the sensitivity and specificity of an application that uses vocal biomarkers to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease. The application will use clinically validated survey instruments and voice recordings to determine the disease status of patients with MCI and Alzheimer's disease. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity and specificity, the application diagnosis will be compared against the physician's clinical diagnosis.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females between the ages of 50 and above
Willing and capable of participating in all aspects of the study
Willing and capable of giving informed consent
Diagnosis of MCI or Alzheimer's by the physician
For the control group: Without diagnosis of MCI or Alzheimer's or other types of dementia
You may not be if
Subject must be able to speak and read with fluency in the English language.
All participants below 50 years
Failure to provide informed consent
Individuals with the following medical conditions will be excluded:
i) Parkinson's disease ii) Huntington's disease iii) Cancer and active cancer treatments
Persons with speech characteristics (heavy accents, slurring, stuttering, etc.) that would interfere with voice recording or voice analysis
